Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP03810056.6Aexternal-prioritypatent/EP1569912B1/en
Application filed by Pharmacyclics, Inc.filedCriticalPharmacyclics, Inc.
Publication of CY1116541T1publicationCriticalpatent/CY1116541T1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με μια καινοτόμο ένωση αναστολέων Τύπου I των παραγόντων Vlla, ΙΧα, Χα, ΧΙα, ιδιαίτερα του παράγοντα Vlla, τις φαρμακευτικές συνθέσεις που περιέχουν αυτούς τους αναστολείς και τις μεθόδους χρήσης αυτών των αναστολέων για τη θεραπεία ή την πρόληψη θρομβοεμβολικών διαταραχών, καρκίνου ή ρευματοειδούς αρθρίτιδας. Περιγράφονται επίσης οι διαδικασίες παρασκευής αυτών των αναστολέων.The present invention relates to an innovative compound of Type I inhibitors of Vlla, IXa, Xa, XIa agents, in particular Vlla, the pharmaceutical compositions containing these inhibitors and the methods of using these inhibitors for the treatment or prevention of thromboembolic disorders. cancer or rheumatoid arthritis. The procedures for preparing these inhibitors are also described.
CY20151100658T2002-01-032015-07-29
2- (2-Hydroxydiphenyl-3-yl) -1H-benzoimidazolo-5-carboxamidine derivative as inhibitors of factor VIIA
CY1116541T1
(en)
cobimetinib, optionally in any form protected by the basic patent, including harmaceutically acceptable salts and sovates thereof, particularly cobimetinib hemifumarate